300347 泰格医药
已收盘 04-10 15:00:00
资讯
新帖
简况
泰格医药新注册《基于Excel的数据自动提取工具软件V1.0》项目的软件著作权
证券之星 · 04-03
泰格医药新注册《基于Excel的数据自动提取工具软件V1.0》项目的软件著作权
泰格医药新注册《基于Excel的分包合同生成工具软件V1.0》项目的软件著作权
证券之星 · 04-02
泰格医药新注册《基于Excel的分包合同生成工具软件V1.0》项目的软件著作权
泰格医药：与某全球龙头MNC签署战略合作协议 参与其全球早期临床研究策略制定
人民财讯 · 04-01
泰格医药：与某全球龙头MNC签署战略合作协议 参与其全球早期临床研究策略制定
泰格医药涨5.98%，东吴证券一个月前给出“买入”评级
证券之星 · 04-01
泰格医药涨5.98%，东吴证券一个月前给出“买入”评级
泰格医药2025年归母净利润大增119%，扣非净利润下滑58%
蓝鲸财经 · 03-31
泰格医药2025年归母净利润大增119%，扣非净利润下滑58%
泰格医药：关于董事会换届选举的公告
证券日报 · 03-30
泰格医药：关于董事会换届选举的公告
泰格医药(300347.SZ)发布2025年度业绩，归母净利润8.88亿元，增长119.15%
智通财经 · 03-30
泰格医药(300347.SZ)发布2025年度业绩，归母净利润8.88亿元，增长119.15%
泰格医药(03347)建议委任萧耀熙为独立非执行董事
智通财经 · 03-30
泰格医药(03347)建议委任萧耀熙为独立非执行董事
泰格医药获Schroders PLC增持38.72万股 每股作价约37.53港元
新浪港股 · 03-30
泰格医药获Schroders PLC增持38.72万股 每股作价约37.53港元
3月27日泰格医药涨5.26%，中欧医疗健康混合A基金重仓该股
证券之星 · 03-27
3月27日泰格医药涨5.26%，中欧医疗健康混合A基金重仓该股
泰格医药（300347）披露董事会会议召开日期公告，3月18日股价上涨0.08%
证券之星 · 03-18
泰格医药（300347）披露董事会会议召开日期公告，3月18日股价上涨0.08%
股市必读：3月13日泰格医药现220.44万元大宗交易
证券之星 · 03-16
股市必读：3月13日泰格医药现220.44万元大宗交易
3月13日泰格医药现220.44万元大宗交易
证券之星 · 03-13
3月13日泰格医药现220.44万元大宗交易
泰格医药（300347）发布2026年第一次临时股东会决议公告，3月5日股价上涨1.27%
证券之星 · 03-05
泰格医药（300347）发布2026年第一次临时股东会决议公告，3月5日股价上涨1.27%
大和：升泰格医药(03347)目标价至45港元 上调收入预测
智通财经 · 03-04
大和：升泰格医药(03347)目标价至45港元 上调收入预测
泰格医药(03347)完成出售上海观合医药全部已发行股本
智通财经 · 03-03
泰格医药(03347)完成出售上海观合医药全部已发行股本
东吴证券：给予泰格医药买入评级
证券之星 · 02-15
东吴证券：给予泰格医药买入评级
里昂：降泰格医药(03347)目标价至59.9港元 续予“跑赢大市”评级
智通财经 · 02-12
里昂：降泰格医药(03347)目标价至59.9港元 续予“跑赢大市”评级
港股异动 | 泰格医药(03347)尾盘跌超5% 扣非利润下跌逾四成 机构称股价已反映利好因素
智通财经 · 02-12
港股异动 | 泰格医药(03347)尾盘跌超5% 扣非利润下跌逾四成 机构称股价已反映利好因素
扣非归母净利润下跌逾40%，泰格医药(03347)何以在二级市场量价齐升？
智通财经 · 02-10
扣非归母净利润下跌逾40%，泰格医药(03347)何以在二级市场量价齐升？
加载更多
公司概况
公司名称：
杭州泰格医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2012-08-17
主营业务：
杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织（CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查、培训等服务、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像、实验室。
发行价格：
37.88
{"stockData":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":57.86,"timestamp":1775804604000,"preClose":55.8,"halted":0,"volume":16503904,"delay":0,"changeRate":0.0369,"floatShares":566000000,"shares":861000000,"eps":1.5919,"marketStatus":"已收盘","change":2.06,"latestTime":"04-10 15:00:00","open":55.8,"high":58.33,"low":55.55,"amount":946000000,"amplitude":0.0498,"askPrice":57.86,"askSize":29,"bidPrice":57.85,"bidSize":13,"shortable":0,"etf":0,"ttmEps":1.5919,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":55.8,"symbolType":"stock","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":61.38,"lowLimit":50.22,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":861026050,"isCdr":false,"pbRate":2.29,"roa":"--","peRate":36.346504,"roe":"4.29%","epsLYR":1.04,"committee":-0.84375,"marketValue":49819000000,"turnoverRate":0.0291,"status":0,"hkstockBrief":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":43.14,"timestamp":1775808560007,"preClose":41.5,"halted":0,"volume":2712216,"delay":0,"premium":"-34.86"},"floatMarketCap":32761000000},"requestUrl":"/m/hq/s/300347","defaultTab":"news","newsList":[{"id":"2624568929","title":"泰格医药新注册《基于Excel的数据自动提取工具软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2624568929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624568929?lang=zh_cn&edition=full","pubTime":"2026-04-03 02:17","pubTimestamp":1775153832,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰格医药新注册了《基于Excel的数据自动提取工具软件V1.0》项目的软件著作权。今年以来泰格医药新注册软件著作权6个，较去年同期增加了50%。结合公司2025年年报财务数据，2025年公司在研发方面投入了2.58亿元，同比增8.08%。通过天眼查大数据分析，杭州泰格医药科技股份有限公司共对外投资了60家企业，参与招投标项目51次；财产线索方面有商标信息79条，专利信息18条，著作权信息179条；此外企业还拥有行政许可45个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300001860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","LU1146622755.USD","300347","BK1576","03347","BK0174","BK0077","BK1141","BK1583","LU1820825898.SGD","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624545579","title":"泰格医药新注册《基于Excel的分包合同生成工具软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2624545579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624545579?lang=zh_cn&edition=full","pubTime":"2026-04-02 02:04","pubTimestamp":1775066656,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰格医药新注册了《基于Excel的分包合同生成工具软件V1.0》项目的软件著作权。今年以来泰格医药新注册软件著作权5个，较去年同期增加了25%。结合公司2025年年报财务数据，2025年公司在研发方面投入了2.58亿元，同比增8.08%。通过天眼查大数据分析，杭州泰格医药科技股份有限公司共对外投资了60家企业，参与招投标项目51次；财产线索方面有商标信息79条，专利信息18条，著作权信息179条；此外企业还拥有行政许可45个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200000796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK1583","03347","LU1820825898.SGD","300347","BK1141","BK0174","BK0216","LU1146622755.USD","BK1576","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624595533","title":"泰格医药：与某全球龙头MNC签署战略合作协议 参与其全球早期临床研究策略制定","url":"https://stock-news.laohu8.com/highlight/detail?id=2624595533","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624595533?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:19","pubTimestamp":1775031540,"startTime":"0","endTime":"0","summary":"【泰格医药：与某全球龙头MNC签署战略合作协议 参与其全球早期临床研究策略制定】泰格医药3月30日在业绩说明会上表示，开年业务亮点：与某全球龙头MNC签署战略合作协议，参与其全球早期临床研究策略制定，提供全方位支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013691912750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0174","BK1576","BK0216","BK1141","03347","LU1820825898.SGD","BK0028","BK1583","LU1146622755.USD","BK0077","300347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624595849","title":"泰格医药涨5.98%，东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2624595849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624595849?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:16","pubTimestamp":1775031411,"startTime":"0","endTime":"0","summary":"今日泰格医药涨5.98%，收盘报57.05元。2026年2月15日，东吴证券研究员朱国广发布了对泰格医药的研报《泰格医药：临床CRO龙头，扬帆启航新征程》，该研报对泰格医药给出“买入”评级。研报中预计2025-2027年营收71.29/80.19/93.27亿元，同比+7.97%/12.48%/16.31%；归母净利润约11.14/13.57/18.17亿元，同比+175%/22%/34%，对应PE为47/39/29X，首次覆盖，给予“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为光大证券的宋硕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100029123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","03347","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589907","title":"泰格医药2025年归母净利润大增119%，扣非净利润下滑58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589907","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623589907?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:17","pubTimestamp":1774959423,"startTime":"0","endTime":"0","summary":"公司2025年归母净利润达8.88亿元，同比增长119.15%，但扣除非经常性损益后的净利润为3.55亿元，同比下降58.47%。非经常性损益总额为5.33亿元，占归母净利润比重达59.99%，接近六成。该板块毛利率由29.56%下滑至20.09%，降幅达9.47个百分点，直接导致公司整体毛利率由33.27%下降至26.53%，降幅6.74个百分点。该板块虽仍为第二大业务板块，但其收入占比已退居次席，且盈利能力弱化对扣非净利润产生实质性冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774954342729329489","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["03347","300347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623346850","title":"泰格医药：关于董事会换届选举的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2623346850","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623346850?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:31","pubTimestamp":1774877460,"startTime":"0","endTime":"0","summary":"证券日报网讯3月30日，泰格医药发布公告称，2026年3月30日，公司召开第五届董事会第二十三次会议，审议通过《关于公司董事会换届选举暨第六届董事会董事候选人提名的议案》，提名叶小平先生、曹晓春女士、吴灏先生、闻增玉先生为公司第六届董事会执行董事候选人；提名袁华刚先生、刘毓文女士、萧耀熙先生为公司第六届董事会独立非执行董事候选人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303689149064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03347","BK0174","BK0216","BK0028","BK0077","BK1576","LU1820825898.SGD","LU1146622755.USD","BK1583","300347","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311294","title":"泰格医药(300347.SZ)发布2025年度业绩，归母净利润8.88亿元，增长119.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311294","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623311294?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:06","pubTimestamp":1774868809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(300347.SZ)发布2025年年度报告，该公司营业收入为68.33亿元，同比增长3.48%。归属于上市公司股东的净利润为8.88亿元，同比增长119.15%。归属于上市公司股东的扣除非经常性损益的净利润为3.55亿元，同比减少58.47%。基本每股收益为1.04元。此外，拟向全体股东每10股派发现金红利1.26元(含税)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300347","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623318929","title":"泰格医药(03347)建议委任萧耀熙为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2623318929","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623318929?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:09","pubTimestamp":1774861796,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，根据提名委员会的推荐意见，董事会建议：(1)重选叶小平博士、曹晓春女士及闻增玉先生为第六届董事会的执行董事;(2)重选袁华刚先生及刘毓文女士为第六届董事会的独立非执行董事;及(3)委任萧耀熙先生为第六届董事会的独立非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1141","BK1576","BK0028","300347","LU1820825898.SGD","BK0174","03347","BK0077","BK1583","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623366195","title":"泰格医药获Schroders PLC增持38.72万股 每股作价约37.53港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623366195","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623366195?lang=zh_cn&edition=full","pubTime":"2026-03-30 07:37","pubTimestamp":1774827420,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，3月24日，Schroders PLC增持泰格医药（03347）38.72万股，每股作价37.5304港元，总金额约为1453.18万港元。增持后最新持股数目为631.53万股，最新持股比例为5.13%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-30/doc-inhsthzk6657633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1146622755.USD","03347","BK0028","BK1583","LU1820825898.SGD","BK1576","BK0174","BK1141","BK0077","BK0216","300347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622849829","title":"3月27日泰格医药涨5.26%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849829?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:17","pubTimestamp":1774599425,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日泰格医药涨5.26%，收盘报53.45元，换手率2.66%，成交量15.06万手，成交额7.9亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共96家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.6652，较上一交易日下跌1.25%，近一年上涨5.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1141","LU1146622755.USD","LU1820825898.SGD","300347","BK1576","BK0174","159760","03347","BK1583","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620825262","title":"泰格医药（300347）披露董事会会议召开日期公告，3月18日股价上涨0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620825262?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:27","pubTimestamp":1773844036,"startTime":"0","endTime":"0","summary":"截至2026年3月18日收盘，泰格医药报收于52.99元，较前一交易日上涨0.08%，最新总市值为456.26亿元。该股当日开盘52.98元，最高53.15元，最低52.3元，成交额达4.06亿元，换手率为1.36%。近日，杭州泰格医药科技股份有限公司发布H股公告，宣布将于2026年3月30日举行董事会会议，审议及批准公司及其附属公司截至2025年12月31日止年度的全年业绩及其刊发，并考虑建议派发末期股息（如适用）。公告发布日期为2026年3月18日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800040749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","BK1576","LU1146622755.USD","03347","BK1141","BK1583","BK0077","LU1820825898.SGD","BK0174","BK0216","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619884483","title":"股市必读：3月13日泰格医药现220.44万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2619884483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619884483?lang=zh_cn&edition=full","pubTime":"2026-03-16 03:36","pubTimestamp":1773603373,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，泰格医药报收于55.11元，下跌1.25%，换手率1.91%，成交量10.84万手，成交额5.99亿元。当日关注点来自交易信息汇总：3月13日主力资金净流入40.38万元，散户资金积极进场，游资呈明显流出态势。来自交易信息汇总：当日发生220.44万元大宗交易，反映个股存在特定机构或大额交易动向。大宗交易3月13日泰格医药现220.44万元大宗交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1576","BK1141","BK0028","BK0216","LU1146622755.USD","BK0174","BK0077","03347","300347","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619957160","title":"3月13日泰格医药现220.44万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2619957160","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619957160?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:11","pubTimestamp":1773393118,"startTime":"0","endTime":"0","summary":"证券之星消息，3月13日泰格医药发生大宗交易，交易数据如下：大宗交易成交价格55.11元，成交4万股，成交金额220.44万元，买方营业部为机构专用，卖方营业部为机构专用。近三个月该股共发生1笔大宗交易，合计成交400.0手。该股近期无解禁股上市。截至2026年3月13日收盘，泰格医药报收于55.11元，下跌1.25%，换手率1.91%，成交量10.84万手，成交额5.99亿元。该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为77.88。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300028929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1820825898.SGD","BK0216","03347","BK1576","BK0028","BK0174","BK1583","BK0077","300347","BK1141","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617523220","title":"泰格医药（300347）发布2026年第一次临时股东会决议公告，3月5日股价上涨1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523220","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617523220?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:17","pubTimestamp":1772720236,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，泰格医药报收于56.77元，较前一交易日上涨1.27%，最新总市值为488.8亿元。公司于近日发布《2026年第一次临时股东会决议的公告》。公告显示，杭州泰格医药科技股份有限公司于2026年3月5日召开2026年第一次临时股东会，会议采用现场与网络投票相结合方式，审议通过《关于变更公司注册地址及修订<公司章程>的议案》。A股及H股股东合计457人出席，代表有表决权股份431,255,969股，占公司有表决权股份总数的50.4309%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500039411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK1583","03347","LU1820825898.SGD","300347","BK1141","BK0174","BK0216","LU1146622755.USD","BK1576","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616304292","title":"大和：升泰格医药(03347)目标价至45港元 上调收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2616304292","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616304292?lang=zh_cn&edition=full","pubTime":"2026-03-04 10:18","pubTimestamp":1772590731,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，上调对泰格医药的2026至2027年收入预测1%至7%，但下调同期每股盈利预测8%至12%，因调低毛利率并上调销售、行政开支及研发开支。维持“持有”评级，目标价由38港元升至45港元。泰格医药发盈喜，预期2025年收入同比增长1%至16%，至66.6亿至76.8亿元人民币(下同)，在2024年跌11%后重拾增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","300347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616349415","title":"泰格医药(03347)完成出售上海观合医药全部已发行股本","url":"https://stock-news.laohu8.com/highlight/detail?id=2616349415","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616349415?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:05","pubTimestamp":1772535909,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，有关出售上海观合医药科技股份有限公司(目标公司)的全部已发行股本相关事宜。股份转让协议中所载的所有先决条件均已获达成，而出售事项于2026年3月3日根据股份转让协议的条款及条件完成。于完成出售事项后，目标公司及其子公司(统称“目标集团”)将仍作为本公司的子公司。目标集团的财务业绩将并入方达集团的财务报表。由于出售事项属于本集团内部交易，出售事项不会对本集团的综合财务状况表产生任何重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1515","BK1574","BK1583","BK0216","LU1820825898.SGD","BK0028","BK1161","159938","BK1576","03347","BK0174","300347","LU1146622755.USD","09939","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611429171","title":"东吴证券：给予泰格医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2611429171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611429171?lang=zh_cn&edition=full","pubTime":"2026-02-15 09:10","pubTimestamp":1771117827,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对泰格医药进行研究并发布了研究报告《泰格医药：临床CRO龙头，扬帆启航新征程》，给予泰格医药买入评级。国内临床CRO行业经历激烈的价格竞争，供给优化，泰格医药龙头市占率持续提升，新签订单加速，有望迎来量价齐升，业绩修复增长潜力大。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为77.88。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500001037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","300347","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610912794","title":"里昂：降泰格医药(03347)目标价至59.9港元 续予“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2610912794","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610912794?lang=zh_cn&edition=full","pubTime":"2026-02-12 15:29","pubTimestamp":1770881373,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，下调泰格医药(03347) 2027财年盈测7%，以反映长期投资收益的不确定因素增加。该行续予泰格医药“跑赢大市”评级，当中将H股目标价由68.2港元下调至59.9港元，并将泰格医药(300347.SZ)A股目标价由81.9元人民币降至72元人民币。泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能力。由于短期利好因素已反映在股价，相信其风险与回报已趋于平衡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300347","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610691478","title":"港股异动 | 泰格医药(03347)尾盘跌超5% 扣非利润下跌逾四成 机构称股价已反映利好因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2610691478","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610691478?lang=zh_cn&edition=full","pubTime":"2026-02-12 15:12","pubTimestamp":1770880368,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，泰格医药尾盘跌超5%，截至发稿，跌4.85%，报51港元，成交额1.3亿港元。消息面上，泰格医药近日公告，此预计2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%；归属于上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%；归属于上市公司股东的扣除非经常性损益后的净利润约3.3亿-4.9亿元，同比下降61%至43%。该行下调泰格医药2027财年盈测7%，以反映长期投资收益的不确定因素增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK0028","BK4588","LU1820825898.SGD","BK1141","BK0077","BK4585","BK1576","VXUS","300347","BK0174","LU1146622755.USD","BK0216","VT","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610613952","title":"扣非归母净利润下跌逾40%，泰格医药(03347)何以在二级市场量价齐升？","url":"https://stock-news.laohu8.com/highlight/detail?id=2610613952","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610613952?lang=zh_cn&edition=full","pubTime":"2026-02-10 14:21","pubTimestamp":1770704466,"startTime":"0","endTime":"0","summary":"近日， 泰格医药的股价出现了一波明显的止跌反弹的趋势。但之后，泰格医药股价又迎来近半个月的技术性下跌，于1月28日跌破50港元。而导致这一盘面变化的根本原因或在于泰格医药披露的2025年年报业绩预告。并且当日是一个典型的“量价齐升”走势，泰格医药当日股票成交量达到704.77万股，展示出场外持币投资者较为强烈的买入意愿。而这已初步反映在了泰格医药此次披露的业绩预告中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","300347"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776037625938,"stockEarnings":[{"period":"1week","weight":0.0463},{"period":"1month","weight":0.0232},{"period":"3month","weight":-0.0387},{"period":"6month","weight":0.0403},{"period":"1year","weight":0.2993},{"period":"ytd","weight":0.0205}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州泰格医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2012-08-17","address":"浙江省杭州市滨江区浦沿街道陆家潭街508号6层601-610室","registeredCapital":"86102万元","survey":" 杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织（CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查、培训等服务、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像、实验室。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,300347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}